Factor V" />
Korean J Hematol 2008; 43(3):
Published online September 30, 2008
https://doi.org/10.5045/kjh.2008.43.3.190
© The Korean Society of Hematology
김소연 김현경 김선회 조한익
서울대학교 의과대학 검사의학교실, 외과학교실
Acquired inhibitor of coagulation factor V is a rare clinical condition and may cause significant morbidity and mortality. We report here the first Korean case of acquired isolated factor V inhibitor developed in a 73-year-old male patient after surgery for pancreatic head carcinoma. At post-operation day 2, intra-abdominal bleeding was recognized that was associated with a prolonged prothrombin time and activated partial thromboplastin time. The prolongation of both conditions was not corrected by a mixing test and factor V activity was reported to be 2%. Quantified titers of inhibitors were increased from 3.5 Bethesda unit to 8.4 Bethesda unit during follow-up analysis. In spite of the treatment with steroids and intravenous immunoglobulins, the case ended fatally. When acquired bleeding tendency with prolonged coagulation screening test is observed, evaluation of inhibitors of coagulation factors may be essential for the diagnosis and following appropriate management of the condition. (Korean J Hematol 2008; 43:190-193.)
Keywords Factor V, Blood coagulation factor, Inhibitor
Korean J Hematol 2008; 43(3): 190-193
Published online September 30, 2008 https://doi.org/10.5045/kjh.2008.43.3.190
Copyright © The Korean Society of Hematology.
김소연 김현경 김선회 조한익
서울대학교 의과대학 검사의학교실, 외과학교실
So Yeon Kim, Hyun Kyung Kim, Sun-Whe Kim, Han-Ik Cho
Departments of Laboratory Medicine and Surgery, Seoul National University College of Medicine, Seoul, Korea
Acquired inhibitor of coagulation factor V is a rare clinical condition and may cause significant morbidity and mortality. We report here the first Korean case of acquired isolated factor V inhibitor developed in a 73-year-old male patient after surgery for pancreatic head carcinoma. At post-operation day 2, intra-abdominal bleeding was recognized that was associated with a prolonged prothrombin time and activated partial thromboplastin time. The prolongation of both conditions was not corrected by a mixing test and factor V activity was reported to be 2%. Quantified titers of inhibitors were increased from 3.5 Bethesda unit to 8.4 Bethesda unit during follow-up analysis. In spite of the treatment with steroids and intravenous immunoglobulins, the case ended fatally. When acquired bleeding tendency with prolonged coagulation screening test is observed, evaluation of inhibitors of coagulation factors may be essential for the diagnosis and following appropriate management of the condition. (Korean J Hematol 2008; 43:190-193.)
Keywords: Factor V, Blood coagulation factor, Inhibitor
Novie A. Chozie, Djajadiman Gatot, Bambang Sudarmanto, Susi Susanah, Rini Purnamasari, Pudjo Hagung Widjajanto, Susanto Nugroho, Olga Rasiyanti, Dian Puspitasari, Muhammad Riza, Maria C. Shanty Larasati, Sri Suryo Adiyanti, Made Citra Saraswati, Fitri Primacakti, on behalf of the Pediatric Hematology-Oncology Working Group of the Indonesian Pediatric Society
Blood Res 2022; 57(4): 272-277Ju Young Kim, Chur Woo You
Blood Res 2019; 54(3): 204-209Myung Hee Han, and Young Shil Park
Blood Res 2013; 48(4): 282-286